{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:30:37Z","timestamp":1792794637697,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Assistance Publique Hopitaux de Paris and Universit\u00e9 Paris Cit\u00e9","id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Antiphospholipid syndrome (APS) is an acquired autoimmune prothrombotic condition. Vascular liver disorders (VLD), such as portal vein thrombosis (PVT), Budd\u2013Chiari syndrome (BCS) and porto-sinusoidal vascular disorder (PSVD), are rare and related to an underlying hypercoagulable state in most cases. We aimed to describe the clinical and immunological features of APS patients with VLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study is a national, multicentre, retrospective study of APS patients followed in four French tertiary university centres, including three national referral centres for rare autoimmune diseases. Clinical, serological and liver characteristics at diagnosis of APS patients with VLD were collected. New thrombotic events and major bleeding during follow-up were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-one VLD were reported in 34 APS patients (59% women; mean age 35+\/\u221215\u2009years; 65% of primary APS) including PVT (n\u2009=\u200926\/41, 63%), BCS (n\u2009=\u200912\/41, 29%) and PSVD (n\u2009=\u20093\/41, 7%). VLD was the first thrombotic event in 79% (n\u2009=\u200927\/34) of patients. Fifteen patients (n\u2009=\u200915\/34, 44%) had portal hypertension, including 10 (n\u2009=\u200910\/34, 29%) with esophageal varices at the time of VLD diagnosis. All patients were treated with oral anticoagulants including VKA in all but one case. Over a median of 9.5 (5; 14) years of follow-up, 62% (n\u2009=\u200921\/34) of patients displayed a new thrombotic event and 26% (n\u2009=\u20099\/34) suffered major bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although rare, VLD may be the presenting manifestation of APS. APS patients with VLD are at high risk of both recurrent thrombotic events and major bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf191","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:29:12Z","timestamp":1744115352000},"page":"4614-4621","source":"Crossref","is-referenced-by-count":2,"title":["Vascular liver disorders in patients with antiphospholipid syndrome: a national retrospective multicentre study"],"prefix":"10.1093","volume":"64","author":[{"given":"Mathilde","family":"Katims","sequence":"first","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne, Universit\u00e9 Paris Cit\u00e9, AP-HP, H\u00f4pital Bichat , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pineton de Chambrun","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence du Lupus, Syndrome des Antiphospholipides et autres Maladies Auto-immunes Rares, Sorbonne Universit\u00e9, AP-HP, H\u00f4pital La Piti\u00e9-Salp\u00eati\u00e8re, Institut E3M, Service de M\u00e9decine Interne 2 , Paris,","place":["France"]},{"name":"Institut de Cardiologie, Service de M\u00e9decine Intensive R\u00e9animation, Sorbonne Universit\u00e9, AP-HP, H\u00f4pital La Piti\u00e9-Salp\u00eati\u00e8re , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Yelnik","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne, Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares du Nord et Nord-Ouest de France, Centre Hospitalier Universitaire, H\u00f4pital Huriez , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Clarke","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne, Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques rares Ile-de-France, Universit\u00e9 Paris Cit\u00e9, AP-HP, H\u00f4pital Cochin , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Papo","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence du Lupus, Syndrome des Antiphospholipides et autres Maladies Auto-immunes Rares, Sorbonne Universit\u00e9, AP-HP, H\u00f4pital La Piti\u00e9-Salp\u00eati\u00e8re, Institut E3M, Service de M\u00e9decine Interne 2 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence du Lupus, Syndrome des Antiphospholipides et autres Maladies Auto-immunes Rares, Sorbonne Universit\u00e9, AP-HP, H\u00f4pital La Piti\u00e9-Salp\u00eati\u00e8re, Institut E3M, Service de M\u00e9decine Interne 2 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lambert","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne, Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques Rares du Nord et Nord-Ouest de France, Centre Hospitalier Universitaire, H\u00f4pital Huriez , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Roland-Nicaise","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Immunologie, Universit\u00e9 Paris Cit\u00e9, AP-HP, Inserm UMR 1152, PHERE, H\u00f4pital Bichat , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Plessier","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9patologie, Centre de r\u00e9f\u00e9rence des Maladies Vasculaires du Foie, Universit\u00e9 Paris Cit\u00e9, AP-HP, H\u00f4pital Beaujon , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Delaval","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne, Universit\u00e9 Paris Cit\u00e9, AP-HP, H\u00f4pital Bichat , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Papo","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne, Universit\u00e9 Paris Cit\u00e9, AP-HP, H\u00f4pital Bichat , Paris,","place":["France"]},{"name":"INSERM UMR 1149, Centre de Recherche sur l\u2019Inflammation, Laboratoire d\u2019Excellence Inflamex , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Rautou","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9patologie, Centre de r\u00e9f\u00e9rence des Maladies Vasculaires du Foie, Universit\u00e9 Paris Cit\u00e9, AP-HP, H\u00f4pital Beaujon , Paris,","place":["France"]},{"name":"INSERM UMR 1149, Centre de Recherche sur l\u2019Inflammation, Laboratoire d\u2019Excellence Inflamex , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-9021","authenticated-orcid":false,"given":"Nathalie","family":"Costedoat Chalumeau","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne, Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes Syst\u00e9miques rares Ile-de-France, Universit\u00e9 Paris Cit\u00e9, AP-HP, H\u00f4pital Cochin , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6544-234X","authenticated-orcid":false,"given":"Karim","family":"Sacre","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne, Universit\u00e9 Paris Cit\u00e9, AP-HP, H\u00f4pital Bichat , Paris,","place":["France"]},{"name":"INSERM UMR 1149, Centre de Recherche sur l\u2019Inflammation, Laboratoire d\u2019Excellence Inflamex , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2025080115374674800_keaf191-B1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2025080115374674800_keaf191-B2","doi-asserted-by":"crossref","first-page":"SI24","DOI":"10.1093\/rheumatology\/kead571","article-title":"Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations","volume":"63","author":"Gaspar","year":"2024","journal-title":"Rheumatology Oxf Engl"},{"issue":"Suppl 1","key":"2025080115374674800_keaf191-B3","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0049-3848(17)30066-X","article-title":"Antiphospholipid syndrome","volume":"151","author":"Cervera","year":"2017","journal-title":"Thromb Res"},{"key":"2025080115374674800_keaf191-B4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025080115374674800_keaf191-B5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the study of liver diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatol Baltim Md"},{"key":"2025080115374674800_keaf191-B6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2468-1253(19)30047-0","article-title":"Porto-sinusoidal vascular disease: proposal and description of a novel entity","volume":"4","author":"De Gottardi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025080115374674800_keaf191-B7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0168-8278(94)80140-1","article-title":"Antiphospholipid syndrome as the second cause of non-tumorous Budd-Chiari syndrome","volume":"21","author":"Pelletier","year":"1994","journal-title":"J Hepatol"},{"key":"2025080115374674800_keaf191-B8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-200111000-00001","article-title":"Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients","volume":"80","author":"Espinosa","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"2025080115374674800_keaf191-B9","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1080\/07853890.2021.1962964","article-title":"The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies","volume":"53","author":"Zhang","year":"2021","journal-title":"Ann Med"},{"key":"2025080115374674800_keaf191-B10","doi-asserted-by":"crossref","first-page":"630660","DOI":"10.3389\/fmed.2021.630660","article-title":"Early initiation of anticoagulation improves the long-term prognosis in patients with antiphospholipid syndrome associated portal vein thrombosis","volume":"8","author":"You","year":"2021","journal-title":"Front Med"},{"key":"2025080115374674800_keaf191-B11","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/rheumatology\/kem158","article-title":"The abdominal manifestations of the antiphospholipid syndrome","volume":"46","author":"Uthman","year":"2007","journal-title":"Rheumatology"},{"key":"2025080115374674800_keaf191-B12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2025080115374674800_keaf191-B13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost JTH"},{"key":"2025080115374674800_keaf191-B14","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost JTH"},{"key":"2025080115374674800_keaf191-B15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"2025080115374674800_keaf191-B16","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1097\/MD.0000000000000496","article-title":"Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis","volume":"94","author":"Qi","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2025080115374674800_keaf191-B17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1078\/0171-2985-00209","article-title":"Nodular regenerative hyperplasia (NRH) of the liver\u2014a manifestation of \u201corgan-specific antiphospholipid syndrome.\u201d?","volume":"207","author":"Klein","year":"2003","journal-title":"Immunobiology"},{"key":"2025080115374674800_keaf191-B18","first-page":"1683","article-title":"Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies","volume":"29","author":"Chopra","year":"2002","journal-title":"J Rheumatol"},{"key":"2025080115374674800_keaf191-B19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/MBC.0b013e32832d6ce7","article-title":"Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations","volume":"21","author":"DeSancho","year":"2010","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"2025080115374674800_keaf191-B20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11239-009-0356-9","article-title":"The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome","volume":"29","author":"Diz-Kucukkaya","year":"2010","journal-title":"J Thromb Thrombolysis"},{"key":"2025080115374674800_keaf191-B21","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost JTH"},{"key":"2025080115374674800_keaf191-B22","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025080115374674800_keaf191-B23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jhep.2022.08.023","article-title":"Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis","volume":"78","author":"Baiges","year":"2023","journal-title":"J Hepatol"},{"key":"2025080115374674800_keaf191-B24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jhep.2024.04.016","article-title":"Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors","volume":"81","author":"Ollivier-Hourmand","year":"2024","journal-title":"J Hepatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf191\/62899155\/keaf191.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/8\/4614\/62899155\/keaf191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/8\/4614\/62899155\/keaf191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T19:37:57Z","timestamp":1754077077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/8\/4614\/8109435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4,9]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf191","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,9]]}}}